TREA

85510388 - XIGEN

Follow

Information

  • Trademark
  • 85510388
  • Serial Number
    85510388
  • Registration Number
    4405437
  • Filing Date
    January 06, 2012
    13 years ago
  • Registration Date
    September 24, 2013
    11 years ago
  • Transaction Date
    July 14, 2020
    4 years ago
  • Status Date
    June 05, 2020
    4 years ago
  • Published for Opposition Date
    December 11, 2012
    12 years ago
  • Location Date
    September 24, 2013
    11 years ago
  • Status Code
    710
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    KLINE, MATTHEW C
  • Attorney Docket Number
    3325-3-001
    Attorney Name
    David A. Jackson
    Law Office Assigned Location Code
    L30
  • Owners
Information
Mark Drawing Code
4000
Mark Identification
XIGEN
Case File Statements
  • GS0051: Food supplements for medical purposes; pharmaceutical, veterinary and sanitary preparations, namely, anti-inflammatory drugs, inhibitors of cell signalling, anti-cancer drugs, antiinfectives and anti-viral drugs; dietetic substances adapted for medical use, namely, food for babies; adjuvants for medical purposes; proteins for medical purposes; biological preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes; chemico-pharmaceutical preparations for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular and rheumatologic diseases; ferments for pharmaceutical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; hormones for medical purposes; medicinal infusions for medical purposes, namely, for the treatment of inflammatory diseases, for the treatment of inflammatory diseases in the eye or in the gastro-intestinal tract, for the treatment of neurological disorders, for the treatment of dementia, for the treatment of Parkinson's disease, for the treatment of stroke, for the treatment of traumatic brain damage, for the treatment of dry eye, for the treatment of cancer, for the treatment of infections, for the treatment of viral infections, for the treatment of cardiovascular diseases and rheumatologic diseases; chemical reagents for medical or veterinary purposes, excluding anti-viral and HIV pharmaceutical preparations and substances
  • GS0351: Advertising; business management; business administration assistance; providing office functions, providing business analysis and research services
  • GS0421: Scientific and technological services and research, namely, pharmaceutical research in particular drug discovery, and design, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; providing pharmaceutical analysis and research services, excluding pharmaceuticals in the HIV and anti-viral therapeutic areas; design and development of computer hardware and software
Case File Event Statements
  • 6/5/2020 - 4 years ago
    25 - CANCELLED SEC. 8 (6-YR) Type: C8..
  • 9/24/2018 - 6 years ago
    24 - COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Type: REM1
  • 9/24/2013 - 11 years ago
    23 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 8/6/2013 - 11 years ago
    22 - PAPER RECEIVED Type: MAIL
  • 8/20/2013 - 11 years ago
    21 - TTAB RELEASE CASE TO TRADEMARKS Type: TMBN
  • 8/20/2013 - 11 years ago
    20 - OPPOSITION TERMINATED NO. 999999 Type: OP.T
  • 8/20/2013 - 11 years ago
    19 - OPPOSITION DISMISSED NO. 999999 Type: OP.D
  • 7/29/2013 - 11 years ago
    18 - PAPER RECEIVED Type: MAIL
  • 6/7/2013 - 11 years ago
    17 - OPPOSITION INSTITUTED NO. 999999 Type: OP.I
  • 1/3/2013 - 12 years ago
    16 - EXTENSION OF TIME TO OPPOSE RECEIVED Type: ETOF
  • 12/11/2012 - 12 years ago
    15 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/11/2012 - 12 years ago
    14 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/21/2012 - 12 years ago
    13 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/5/2012 - 12 years ago
    12 - LAW OFFICE PUBLICATION REVIEW COMPLETED Type: PREV
  • 11/5/2012 - 12 years ago
    11 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/5/2012 - 12 years ago
    10 - AMENDMENT FROM APPLICANT ENTERED Type: ACEC
  • 11/5/2012 - 12 years ago
    9 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 11/5/2012 - 12 years ago
    8 - ASSIGNED TO LIE Type: ALIE
  • 10/25/2012 - 12 years ago
    7 - PAPER RECEIVED Type: MAIL
  • 4/18/2012 - 12 years ago
    6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 4/18/2012 - 12 years ago
    5 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 4/18/2012 - 12 years ago
    4 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 4/11/2012 - 12 years ago
    3 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/11/2012 - 13 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM Type: NWOS
  • 1/10/2012 - 13 years ago
    1 - NEW APPLICATION ENTERED IN TRAM Type: NWAP